A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies

Trial Profile

A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Zanubrutinib (Primary) ; Obinutuzumab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 09 Dec 2017 Results presented in a BeiGene Media Release.
    • 01 Nov 2017 According to a BeiGene media release, data will be presented at the upcoming 59th American Society of Hematology (ASH) Annual Meeting.
    • 16 Jun 2017 According to a BeiGene media release, as of March 31, 2017, 45 patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and 17 patients with follicular lymphoma (FL) were enrolled in the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top